Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis A portion of the data in this manuscript was presented in at the Fall European Academy of Dermatology and Venereology 23rd Congress in Amsterdam on October 8, 2014.

Journal of the American Academy of Dermatology

Volumn 73, Issue 3, 2015, Pages 410-419.e6

  Menter, Alan ^a   Thaçi, Diamant ^b   Papp, Kim A ^c   Wu, Jashin J ^d   Bereswill, Mareike ^e   Teixeira, Henrique D ^e   Rubant, Simone ^e   Williams, David A ^e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e ABBVIE INC   (United States)

Author keywords

adalimumab; adverse events; long term safety; malignancy; registry; serious infections

Indexed keywords

ADALIMUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; BRONCHITIS; CELLULITIS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEART INFARCTION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; LATENT TUBERCULOSIS; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; SQUAMOUS CELL CARCINOMA; STANDARDIZED MORTALITY RATIO; T CELL LYMPHOMA; THRUSH; TUBERCULOSIS; AGED; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT SAFETY; PROCEDURES; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TIME; TREATMENT OUTCOME; UNITED STATES;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT SAFETY; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84939468643     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.06.038     Document Type: Article

References (24)

1. W. Gulliver Long-term prognosis in patients with psoriasis Br J Dermatol 159 Suppl 2 2008 2 9
2. A.B. Kimball, D. Gladman, J.M. Gelfand, and et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening J Am Acad Dermatol 58 2008 1031 1042
3. E.J. Samarasekera, J.M. Neilson, R.B. Warren, J. Parnham, and C.H. Smith Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis J Invest Dermatol 133 2013 2340 2346
4. H. Yeung, J. Takeshita, N.N. Mehta, and et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study JAMA Dermatol 149 2013 1173 1179
5. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
6. W.P. Gulliver, D. Macdonald, N. Gladney, R. Alaghehbandan, P. Rahman, and K. Adam Baker Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population J Cutan Med Surg 15 2011 37 47
7. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
8. N.H. Shear, M. Hartmann, M. Toledo-Bahena, and et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice Br J Dermatol 171 2014 631 641
9. S. Tyring, K.B. Gordon, Y. Poulin, and et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
10. C. Leonardi, K. Papp, B. Strober, and et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials Am J Clin Dermatol 12 2011 321 337
11. K. Gordon, K. Papp, Y. Poulin, Y. Gu, S. Rozzo, and E.H. Sasso Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL J Am Acad Dermatol 66 2012 241 251
12. A.B. Kimball, K.J. Rothman, G. Kricorian, and et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results J Am Acad Dermatol 72 2014 115 122
13. S. Famenini, E.Y. Sako, and J.J. Wu Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors Am J Clin Dermatol 15 2014 45 50
14. G.R. Burmester, R. Panaccione, K.B. Gordon, M.J. McIlraith, and A.P. Lacerda Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Annals Rheum Diseases 72 2013 517 524
15. K.M. Cordoro, and S.R. Feldman TNF-alpha inhibitors in dermatology Skin Therapy Letter 12 2007 4 6
16. Humira [package insert] 2013 AbbVie Inc North Chicago, IL, USA
17. Enbrel [package insert] 2013 Amgen Thousand Oaks, CA
18. Remicade [package insert] 2013 Janssen Biotech, Inc Horsham, PA
19. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol & Therapeutics 117 2008 244 279
20. A.L. Semble, S.A. Davis, and S.R. Feldman Safety and tolerability of tumor necrosis factor-alpha inhibitors in psoriasis: a narrative review Am J Clin Dermatol 15 2014 37 43
21. J.M. Jackson TNF-alpha inhibitors Derm Ther 20 2007 251 264
22. N. Scheinfeld A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab J Derm Treat 15 2004 280 294
23. X. Mariette, M. Matucci-Cerinic, K. Pavelka, and et al. Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis Annals Rheum Diseases 70 2011 1895 1904
24. A.B. Kimball, D. Pariser, P.S. Yamauchi, and et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis J Am Acad Dermatol 68 2013 756 764